Antiplatelet and Anticoagulant Drugs
Antiplatelets
- Aspirin irreversibly inhibits cyclo-oxygenase impairing platelet synthesis of the prostaglandin thromboxane A2, preventing platelet aggregation.
- Dipyridamole inhibits both the reuptake of adenosine and phosphodiesterase, preventing the degradation of cAMP and thus blocking the platelet aggregation response to ADP.
- Clopidogrel inhibits the binding of ADP to its platelet receptor, preventing platelet aggregation.
- Abciximab, eptifibatide and tirofiban are GPIIb/IIIa inhibitors, inhibiting platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive molecules.
Aspirin Antiplatelet Effect. (Image by Vtvu [CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)])
Anticoagulants
- Unfractionated heparin potentiates the activity of antithrombin, which then inactivates thrombin, factor Xa and other proteases.
- Low molecular weight heparin (LMWH) preparations inhibit factor Xa directly. Inhibition of factor Xa prevents thrombin generation and thrombus development.
- Warfarin is a coumarin derivative that acts by inhibiting vitamin-K dependent clotting factors (factors VII, IX, X and II) as well as the anticoagulant proteins C and S.
- Apixaban, dabigatran, edoxaban and rivaroxaban are new anticoagulants with a novel mode of action:
- Apixaban, edoxaban and rivaroxaban are direct and reversible inhibitors of factor Xa.
- Dabigatran is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet aggregation.